Collagen Solutions PLC Board Appointments (4915Z)
03 September 2018 - 4:00PM
UK Regulatory
TIDMCOS
RNS Number : 4915Z
Collagen Solutions PLC
03 September 2018
Collagen Solutions Plc
(the "Company" or the "Group")
Board Appointments
Delivering on our growth strategy
Collagen Solutions plc (AIM: COS), the developer and
manufacturer of biomaterials and regenerative medicines for the
enhancement and extension of human life, announces the appointment
of Tom Hyland, Chief Operating Officer, and Lou Ruggiero, Chief
Business Officer, to the Board with immediate effect.
Tom Hyland (53), Chief Operating Officer, joined Collagen
Solutions in 2014 bringing experience in the field of collagen
chemistry and the development, manufacturing, validation and
engineering requirements of collagen-based medical devices. Tom has
been involved in bringing a number of collagen-based products to
market and has most recently provided oversight of the Company's
development business and the reconfiguring the Company's Glasgow
operation. Tom has previously worked with a number of global life
science companies including Johnson and Johnson Medical,
Microsulis, Intercell Biomedical, Alere Technologies and
Invitrogen.
Lou Ruggiero (58), joined the Company in April 2018 as Chief
Business Officer to focus on speed of delivery and execution within
the commercial arena. Lou has previously held a number of
commercial roles in sales and general management in the healthcare
and technology industries. Prior to joining Collagen Solutions, Lou
served as Senior Vice President of Sales at Pearson Clinical
Assessments and as Chief Commercial Officer of Hely & Weber
Orthopedics. Prior to this he was Vice President of Sales and
Business Development at Ossur Americas. Previously, Lou spent ten
years as a senior executive and Board Director in the orthopaedic
device industry.
On appointment Tom Hyland will be granted options over 1,500,000
ordinary shares of 1 pence each in the share capital of the Company
exercisable on the market price applicable on the appointment date
with vesting conditions dependent on achieving a closing middle
market price per Share of 10 pence at any time after the date of
grant and on the Company delivering sustainable positive cash flows
from operations (sustained for a period of at least six consecutive
monthly periods).
David Evans, Chairman of Collagen Solutions, said: "We are
delighted that Lou and Tom are joining the Board. Between them they
have a wealth of experience which we believe will help us deliver
on our strategic goals and take us to the next level of
growth."
Tom Hyland
Current Directorships Previous Directorships
-----------------------
Hyland Enterprise and Housing None
Limited
Collagen Solution(UK) Limited
-----------------------
Tom Hyland holds 157,859 ordinary shares in the capital of the
Company.
Lou Ruggiero
Current Directorships Previous Directorships
----------------------------------------
None Instant Bioscan, Tucson, Arizona
Stardust Building Supplies, Phoenix,
Arizona
Grangecroft Consulting, LLC, Phoenix,
Arizona OneSource Medical, LLC,
Phoenix, Arizona
----------------------------------------
Lou Ruggiero holds no ordinary shares in the capital of the
Company.
Enquiries:
Collagen Solutions Plc
Jamal Rushdy, CEO Via Walbrook
Hilary Spence, CFO
Cenkos Securities Plc (Nominated
Adviser and Broker)
Steve Cox (Corporate Finance) Tel: 0207 397 8900
Stephen Keys
Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Helen Cresswell Mob: 07841 917 679
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and
manufacturer of medical grade collagen, tissues, and related
medical devices and components for use in regenerative medicine,
medical devices and in-vitro diagnostics and research. The Company
is also expanding its range of biomaterials-based finished medical
devices based on its internal and acquired intellectual property
for commercialisation with partners via licensing and distribution
arrangements, including ChondroMimetic(R). The Company's products
are used in a wide variety of applications including orthopaedics,
cardiovascular, dental, plastic surgery, wound healing, neurology
and urology.
For more information go to: www.collagensolutions.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOADLLFBVKFZBBF
(END) Dow Jones Newswires
September 03, 2018 02:00 ET (06:00 GMT)
Collagen Solutions (LSE:COS)
Historical Stock Chart
From Apr 2024 to May 2024
Collagen Solutions (LSE:COS)
Historical Stock Chart
From May 2023 to May 2024